Anesthesia and Nesfatin-1: What You Need to Know About Surgery's Impact
"Uncover how common anesthetics affect a key hormone involved in stress response and cardiovascular health."
Surgery can be a stressful event for the body, triggering a cascade of responses involving hormones and various physiological systems. Among these, Nesfatin-1, a peptide involved in cardiovascular regulation and stress responses, has garnered increasing attention.
Laparoscopic cholecystectomy, a common surgical procedure, presents a unique opportunity to study the impact of anesthesia on Nesfatin-1 levels. Anesthetics are essential for patient comfort and safety during surgery, but how do they influence this key stress-related hormone?
This article explores the findings of a randomized controlled trial investigating the effects of two common volatile anesthetics, desflurane and sevoflurane, on Nesfatin-1 levels in patients undergoing laparoscopic cholecystectomy. Understanding this interplay could refine anesthetic practices and improve patient outcomes.
Current Evidence on Surgical Nesfatin-1 Changes
Research has examined nesfatin-1 changes in patients undergoing laparoscopic cholecystectomy, including whether desflurane and sevoflurane produce different effects on plasma nesfatin-1 levels. Another study investigated the relationship between stress, fasting, fluid restriction, endocrine responses, and nesfatin-1 before anesthesia induction. A 2024 review describes nesfatin-1 as a regulator of inflammation, focusing on NFκB signaling, pro-inflammatory cytokine production, and apoptosis. These findings indicate that anesthesia and perioperative stress are relevant research contexts, but they do not establish a universal clinical effect.
What Current Evaluation Involves
Current research approaches include measuring nesfatin-1 in relation to perioperative stress, fasting, and fluid restriction, as well as investigating its possible use as a biomarker in neurological disease. A review cited reduced nesfatin-1 levels in patients with ischemic stroke, illustrating the peptide's potential biomarker role outside anesthesia. However, nesfatin-1 lacks FDA and EMA approval, and available human safety data remain limited beyond preclinical studies. These limitations mean that nesfatin-1 should be treated as an investigational research subject rather than an established anesthesia treatment or routine clinical test.
An Emerging Research Field
The history of nesfatin-1 research is still developing, particularly in relation to anesthesia and surgery. Early and ongoing investigations have considered its links with energy metabolism, stress, inflammation, and perioperative physiology. The available evidence supports viewing this area as an evolving research field rather than one with settled clinical milestones. Further studies will be needed to clarify how consistently surgical stress and anesthetic exposure affect nesfatin-1.
Does Anesthesia Alter Nesfatin-1 Levels During Surgery?
A recent study published in BMC Anesthesiology investigated whether desflurane and sevoflurane, two commonly used anesthetics, affect Nesfatin-1 levels during laparoscopic cholecystectomy. The study involved 42 patients, aged 30-65 years, with ASA Class I-II status (indicating mild to no systemic disease).
- Study Design: Randomized, controlled trial.
- Participants: 42 patients undergoing laparoscopic cholecystectomy.
- Intervention: Desflurane vs. sevoflurane anesthesia.
- Measurements: Nesfatin-1 levels before and after surgery.
New Directions in Nesfatin-1 Research
Recent research has expanded beyond anesthesia to examine nesfatin-1 in inflammatory and vascular disease. A 2026 study reported that nesfatin-1 limited acute pancreatitis severity by restraining endoplasmic-reticulum-stress-driven pyroptosis and innate immune activation, identifying it as a possible therapeutic candidate. Another 2026 study linked nesfatin-1 from dysfunctional perivascular adipose tissue to pulmonary hypertension and reported endothelial dysfunction through transcriptional and posttranslational downregulation of BMPR1A. In parallel, a recent anesthesia study investigated desflurane and sevoflurane during laparoscopic cholecystectomy, keeping perioperative nesfatin-1 responses within the broader research agenda.
Why Conclusions Remain Limited
The available evidence does not yet justify treating nesfatin-1 as a validated way to predict or improve surgical outcomes. Findings may be influenced by the procedure, anesthetic exposure, fasting, fluid restriction, stress responses, and the underlying health of the patient. Research is also spread across preclinical work, observational investigations, and disease-specific studies, making direct comparisons difficult. These limitations favor cautious interpretation until larger and more clinically focused studies clarify reproducibility and practical value.
Comparing Anesthetic Options
Desflurane has a lower blood-gas partition coefficient than sevoflurane, allowing faster wash-in and wash-out, but a recent comparison reports that clinical relevance may be limited because anesthetic-depth management can equalize emergence times. Separate research has evaluated ciprofol versus propofol for gastrointestinal endoscopy, describing ciprofol as an alternative that can achieve anesthesia at a lower dose with a lower incidence of adverse events. A randomized study specifically examined desflurane and sevoflurane in laparoscopic cholecystectomy while measuring nesfatin-1-related outcomes. These comparisons show that anesthetic selection involves both recovery characteristics and the question of how each drug may interact with perioperative biology.
Key Takeaways and Future Directions
This study suggests that Nesfatin-1 levels are not significantly affected by the choice of desflurane or sevoflurane during laparoscopic cholecystectomy. This finding provides valuable insights into the hormonal response to surgery under different anesthetic regimens.
Interpreting the Overall Evidence
Nesfatin-1 is described as an anorexigenic peptide associated with appetite control and energy balance, but its response after bariatric surgery is reported to be variable. Research on stress, fasting, and fluid restriction before anesthesia induction adds another layer of perioperative complexity. Taken together, these sources support considering nesfatin-1 within a broader network of metabolic and stress-related responses rather than as a standalone measure of surgical impact. The available evidence is informative but does not support a single predictable postoperative pattern.
Technology and the Future of Anesthesia
Reported anesthesia trends for 2025 include AI integration, CRNA independence, hybrid staffing, and growth in outpatient care. Market Research Future estimated the anesthesia drugs market at USD 7.63 billion in 2022 and projected growth from USD 7.95 billion in 2023 to USD 11.5 billion by 2032, with an expected 4.18% compound annual growth rate from 2024 to 2032. Other reporting describes anesthesia as facing rising demand, evolving technology, workforce shortages, reimbursement pressure, and increasing complexity. These developments could create more opportunities for perioperative data collection, although they do not by themselves establish a future clinical role for nesfatin-1.
Nesfatin-1 Beyond Surgery
Human research on nesfatin-1 extends across infertility, assisted reproductive technologies, pregnancy adaptations and complications, the maternal-fetal interface, lactation, and postpartum metabolic recovery. A 2026 review emphasizes that findings across reproduction and early life are inconsistent and proposes a framework for reconciling them. This broader context suggests that nesfatin-1 responses may vary substantially with physiological state and clinical setting. Such variability is an important challenge when attempting to generalize perioperative findings to wider patient populations.
Keeping Patients at the Center
For patients, the practical meaning of nesfatin-1 research remains uncertain because the peptide is still being studied in relation to anesthesia, surgical stress, fasting, and metabolic regulation. Individual responses may differ according to the procedure and the patient's physiological condition. Until clinical evidence becomes more consistent, established perioperative assessment and patient-centered decision-making remain more immediately relevant than experimental nesfatin-1 applications. Research should continue to distinguish promising biological signals from benefits that have been demonstrated in routine care.
While the study offers reassurance regarding the impact of these anesthetics on Nesfatin-1, further research is needed to explore the broader implications of surgical stress on this hormone. Factors such as the duration of surgery, the intensity of postoperative pain, and individual patient characteristics could influence Nesfatin-1 dynamics.
Future studies could also investigate the effects of other anesthetic agents and techniques on Nesfatin-1 levels, as well as explore the potential role of premedication strategies in mitigating stress responses and optimizing patient outcomes. This knowledge can ultimately refine anesthetic practices and enhance patient care.